Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
MetadataShow full item record
Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive (ER+) breast cancer, but the underlying mechanisms are largely unknown. We have identified C-terminal SRC kinase (CSK) as a critical node in a previously unappreciated negative feedback loop that limits the efficacy of current ER-targeted therapies. Estrogen directly drives CSK expression in ER+ breast cancer. At low CSK levels, as is the case in patients with ER+ breast cancer resistant to endocrine therapy and with the poorest outcomes, the p21 protein-activated kinase 2 (PAK2) becomes activated and drives estrogen-independent growth. PAK2 overexpression is also associated with endocrine therapy resistance and worse clinical outcome, and the combination of a PAK2 inhibitor with an ER antagonist synergistically suppressed breast tumor growth. Clinical approaches to endocrine therapy-resistant breast cancer must overcome the loss of this estrogen-induced negative feedback loop that normally constrains the growth of ER+ tumors.
Version of record
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
License start date
Proc Natl Acad Sci U S A, 2018, 115 (31), pp. 7869 - 7878
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenev, T; Gellert, P; Buluwela, L; Harrod, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M-O; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Li, Z; Sikora, MJ; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M (2017-11-30)Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ...
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...
Jeselsohn, R; Cornwell, M; Pun, M; Buchwalter, G; Nguyen, M; Bango, C; Huang, Y; Kuang, Y; Paweletz, C; Fu, X; Nardone, A; De Angelis, C; Detre, S; Dodson, A; Mohammed, H; Carroll, JS; Bowden, M; Rao, P; Long, HW; Li, F; Dowsett, M; Schiff, R; Brown, M (2017-05-30)The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation ...